Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Characteristics at diagnosis of 109 patients with NB

From: BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma

Characteristic

Total

High BPTF

Low BPTF

χ2

P-values

Percent of sample, n (%)

 

55 (50.5)

54 (49.5)

  

Sex, n (%)

   

3.305

0.069

 Male

53 (48.6)

22 (40.0)

31 (57.4)

  

 Female

56 (51.4)

33 (60.0)

23 (42.6)

  

Age (months), n (%)

   

1.155

0.283

  < 18

18 (16.5)

7 (12.7)

11 (20.4)

  

  ≥ 18

91 (83.5)

48 (87.3)

43 (79.6)

  

Staging, n (%)

   

6.694

0.010*

 I-III/IVs

55 (50.5)

21 (38.2)

34 (63.0)

  

 IV

54 (49.5)

34 (61.8)

20 (37.0)

  

Risk group, n (%)

   

5.731

0.017*

 LR or IR

54 (49.5)

21 (38.2)

33 (61.1)

  

 HR

55 (50.5)

34 (61.8)

21 (38.9)

  

MYCN status, n (%)

   

0.057

0.810

 Amplification

15 (13.8)

8 (14.5)

7 (13.0)

  

 Not amplification

94 (86.2)

47 (85.5)

47 (87.0)

  

1p36 status, n (%)

   

0.052

0.819

 LOH

25 (23.6)

13 (24.5)

12 (22.6)

  

 No loss

81 (76.4)

40 (75.5)

41 (77.4)

  

11q23 status, n(%)

   

2.771

0.096

 LOH

34 (32.1)

21 (39.6)

13 (24.5)

  

 No loss

72 (67.9)

32 (60.4)

40 (75.5)

  

PHOX2B, n (%)

   

3.303

0.069

  = 0

51 (46.8)

21 (38.2)

30 (55.6)

  

  > 0

58 (53.2)

34 (61.8)

24 (44.4)

  

LDH (U/L), n (%)

   

1.216

0.749

  ≤ 295

36 (33.0)

18 (32.7)

18 (33.4)

  

 295–500

24 (22.0)

10 (18.2)

14 (25.9)

  

 500–1500

32 (29.4)

18 (32.7)

14 (25.9)

  

  > 1500

17 (15.6)

9 (16.4)

8 (14.8)

  

NSE (ng/l), n (%)

   

4.863

0.088

  ≤ 25

26 (23.9)

12 (21.8)

14 (25.9)

  

 25–100

24 (22.0)

8 (14.5)

16 (29.7)

  

  > 100

59 (54.1)

35 (63.7)

24 (44.4)

  

Primary tumor site, n (%)

   

6.161

0.013*

 Retroperitoneum and adrenal glands

71 (65.1)

42 (76.4)

29 (53.7)

  

 Mediastinum/Pelvic cavity/Neck

38 (34.9)

13 (23.6)

25 ((46.3)

  

Tumor size (cm), n (%)

   

6.262

0.044*

  ≤ 5

26 (23.9)

9 (16.4)

17 (31.5)

  

 5–10

43 (39.4)

20 (36.4)

23 (42.6)

  

  > 10

40 (36.7)

26 (47.2)

14 (25.9)

  

Number of organs with metastasis, n (%)

   

2.711

0.100

  ≤ 3

60 (55.0)

26 (47.3)

34 (63.0)

  

  > 3

49 (45.0)

29 (52.7)

20 (37.0)

  

BM metastasis, n (%)

     

 Yes

49 (45.0)

30 (54.5)

19 (35.2)

4.127

0.042*

 No

60 (55.0)

25 (45.5)

3535353564.8)

  
  1. LR Low-risk, IR Intermediate-risk, HR High-risk, MYCN amplification of the MYCN gene, LDH Lactate dehydrogenase, NSE Neuron-specific enolase, LOH Loss of heterozygosity, BM Bone marrow. * P < 0.05, as assessed by Chi-square test